ReviewMicroorganisms2019
The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant
Review in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility forMicrobiology spectrum · 2026Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Genomic characterisation of extensively drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Ghana.PloS one · 2026Article
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
- Review
- Antimicrobial Resistance Profiles of Multidrug-Resistant Pathogens in a Military Hospital: A Three-Year Study.Cureus · 2025Article
- Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.The Journal of antimicrobial chemotherapy · 2025Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Review
- Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- An Ancient Drug for a Modern Era: Minocycline for the Treatment of Multi-Drug-Resistant Acinetobacter baumannii.Cureus · 2024Article
- Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Antimicrobial susceptibility and genetic characteristics of multi-drug resistantFrontiers in microbiology · 2024Article
- Genetic Determinants ofAntibiotics (Basel, Switzerland) · 2023Article
- Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Efficacy of Cefoperazone Sulbactam in Patients withAntibiotics (Basel, Switzerland) · 2023Review
- Transcriptome Analysis ofInternational journal of environmental research and public health · 2022Article
- Minocycline and the SPR741 Adjuvant Are an Efficacious Antibacterial Combination forAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for multidrug resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.